The Wegovy golden dose: how to use it and what the term really means

The myth: there is one universal 'golden dose' everyone should aim for

This is a question our prescribers hear most weeks, usually from patients who have read that 1.7 mg or 2.4 mg is the dose where Wegovy 'really works'. The short answer is that no single strength is clinically designated as a golden dose, and if you are wondering whether there is truly a golden dose in Wegovy, the evidence suggests it varies considerably from person to person. The phrase grew online from people sharing that their appetite suppression clicked into place at a dose below the licensed maximum (often 1.0 mg or 1.7 mg) and that going higher just brought more nausea without noticeably more hunger reduction.

There is real biology behind the observation. Semaglutide, the active medicine in Wegovy, acts on GLP-1 receptors in the brain and gut, slowing gastric emptying and reducing appetite signals. The dose-response relationship is not perfectly linear for every person; some bodies reach a plateau of appetite suppression earlier than others. That variability is exactly why the schedule is a titration, not a prescription for a fixed endpoint.

The STEP 1 trial (published in the New England Journal of Medicine) studied adults on 2.4 mg over 68 weeks and found an average body-weight reduction of around 15%. Those results are at the standard maintenance dose; they do not mean 2.4 mg is the target for every individual. What they confirm is that the medicine works across the population at that ceiling dose. Whether it is the right ceiling for you is a separate, prescriber-led question.

How the dose schedule actually works, and where the 'golden dose' fits in

The licensed Wegovy dose schedule starts at 0.25 mg for the first four weeks. That starter strength exists primarily to let your digestive system adjust; it is not expected to produce significant appetite suppression at that level. The steps then move to 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg as the standard maintenance, each rung held for roughly four weeks.

A prescriber may choose to keep you at an intermediate dose for longer, or permanently, if you are tolerating it well and losing weight at a clinically appropriate rate. Staying at 1.7 mg is not a failure to reach the finish line, it may simply be the right clinical decision for you. Equally, if gastrointestinal side effects were tough at 1.7 mg and then settled, your prescriber might proceed to 2.4 mg on the basis that your system has adapted. The dose titration chart outlines each step, but it illustrates the path, not the destination.

Since January 2026 the schedule has an additional tier. The MHRA approved a 7.2 mg weekly dose option, initially administered as three 2.4 mg pens; a dedicated single-dose 7.2 mg pen followed in April 2026, as confirmed in the MHRA's announcement on GOV.UK. Clinical trial data reported around 20.7% average weight loss at 7.2 mg over 72 weeks. That is a meaningful step up, but the 7.2 mg option is for BMI of 30 or above, and reaching it still requires a full prescriber review at each stage. Some people may find their own personal Wegovy golden dose well before the new ceiling.

Using the Wegovy pen properly at whatever dose you are prescribed

Whatever dose your prescriber confirms, the injection technique is the same throughout the schedule. Wegovy is a once-weekly subcutaneous injection given into the abdomen, outer thigh or upper arm. Rotate injection sites each week to reduce localised reactions. The pen is pre-filled and pre-set to your current dose; you do not adjust anything manually.

Storage matters. Pens should be kept refrigerated between 2°C and 8°C. Once you have removed a pen from the fridge, refer to the Patient Information Leaflet for the exact window during which it can be kept at room temperature, the NHS medicines information for semaglutide on the NHS website covers storage and administration in plain language. Do not use a pen that has been frozen or left in direct sunlight.

If you miss a dose, the general guidance is to take it as soon as possible, provided there are at least five days before your next scheduled injection. If fewer than five days remain, skip the missed dose and return to your normal weekly schedule. Do not take two doses to compensate. Specific missed-dose questions should go to your prescriber, these are the decisions that depend on exactly where you are in your titration. You can review general pen handling detail in the guide to using the Wegovy four-dose pen.

The practical question: how do you know if you have found your dose?

There is no diagnostic test for reaching a personal golden dose. The signals are practical: appetite is meaningfully reduced between meals, food noise has quietened, you are losing weight at a rate your prescriber considers appropriate, and side effects are tolerable or have settled. If all of those are true at 1.0 mg, there is no clinical imperative to chase a higher number on the label.

What you should not do is adjust doses yourself, delay a titration without telling your prescriber, or stay at a lower dose because you read that someone online 'felt amazing' there. The right dose is the intersection of efficacy and tolerability, for your body, at this point in treatment. That assessment belongs in a clinical review.

If you are considering Wegovy and want a prescriber to assess your suitability, you can find out more about how Wegovy works or explore treatment options more broadly. If you are ready to begin, check your eligibility with our prescribers, the consultation is free, and every case is reviewed by a GPhC-registered Independent Prescriber, not automated software.